TherapeuticsMD, Inc. (NASDAQ: TXMD), a company focused on pharmaceutical royalties, announced its financial results for the full year ended December 31, 2025. The company reported a net loss from continuing operations of $(0.7) million, or $(0.06) per share, which is an improvement of $1.7 million compared to a net loss of $(2.3) million, or $(0.20) per share, for the previous year. License revenues from continuing operations increased significantly, totaling $3.0 million for 2025, a 71.6% increase from $1.8 million in 2024, primarily due to changes in sales of licensed products. Total operating expenses decreased to $7.4 million, down from $7.9 million in 2024, attributed to lower impairment charges, although offset by higher bonus expenses and increased costs related to investor communications. The company continues to evaluate various strategic alternatives, including potential acquisitions or mergers, but has not established a timetable for completion. As of December 31, 2025, the company had cash and cash equivalents of $7.5 million. The report indicates a cautious optimism regarding the company's financial trajectory and operational strategy moving forward.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.